share_log

Firefly Neuroscience | 10-Q: Q3 2024 Earnings Report

Firefly Neuroscience | 10-Q: Q3 2024 Earnings Report

Firefly Neuroscience | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/15 06:32

Moomoo AI 已提取核心信息

Firefly Neuroscience reported Q3 2024 financial results with revenue of $33,000, up 43% YoY, and a net loss of $4.3 million compared to $650,000 in Q3 2023. Operating expenses increased significantly to $4.3 million from $670,000 last year, primarily due to merger-related costs and share-based compensation expenses following the completion of its merger with WaveDancer in August 2024.Research and development expenses rose 124% YoY to $878,000, while selling and marketing expenses increased to $431,000 from $95,000. General and administrative expenses grew substantially to $3 million, driven by management compensation, legal fees, and public company costs. The company ended the quarter with $1.2 million in cash, down from $2.1 million at year-end 2023.Looking ahead, Firefly plans to launch commercial operations for its FDA-cleared Brain Network Analytics (BNA) Platform in the first half of 2025. The company aims to generate revenue through neurologist adoption in the United States and collaborations with pharmaceutical companies, though management noted substantial doubt about the company's ability to continue as a going concern without additional funding.
Firefly Neuroscience reported Q3 2024 financial results with revenue of $33,000, up 43% YoY, and a net loss of $4.3 million compared to $650,000 in Q3 2023. Operating expenses increased significantly to $4.3 million from $670,000 last year, primarily due to merger-related costs and share-based compensation expenses following the completion of its merger with WaveDancer in August 2024.Research and development expenses rose 124% YoY to $878,000, while selling and marketing expenses increased to $431,000 from $95,000. General and administrative expenses grew substantially to $3 million, driven by management compensation, legal fees, and public company costs. The company ended the quarter with $1.2 million in cash, down from $2.1 million at year-end 2023.Looking ahead, Firefly plans to launch commercial operations for its FDA-cleared Brain Network Analytics (BNA) Platform in the first half of 2025. The company aims to generate revenue through neurologist adoption in the United States and collaborations with pharmaceutical companies, though management noted substantial doubt about the company's ability to continue as a going concern without additional funding.
Firefly Neural科学在2024年第三季度报告了财务结果，营业收入为33,000美元，同比增长43%，净亏损为430万美元，较2023年第三季度的650,000美元有所减少。营业费用显著增加，从去年的670,000美元升至430万美元，主要是由于与合并相关的成本和基于股票的补偿费用，这些费用是在2024年8月与WaveDancer完成合并后产生的。研发费用同比增长124%，达到878,000美元，而销售和市场费用则从95,000美元增加到431,000美元。一般和管理费用显著增长至300万美元，主要受到管理补偿、法律费用和上市公司成本的推动。公司在本季度结束时现金为120万美元，较2...展开全部
Firefly Neural科学在2024年第三季度报告了财务结果，营业收入为33,000美元，同比增长43%，净亏损为430万美元，较2023年第三季度的650,000美元有所减少。营业费用显著增加，从去年的670,000美元升至430万美元，主要是由于与合并相关的成本和基于股票的补偿费用，这些费用是在2024年8月与WaveDancer完成合并后产生的。研发费用同比增长124%，达到878,000美元，而销售和市场费用则从95,000美元增加到431,000美元。一般和管理费用显著增长至300万美元，主要受到管理补偿、法律费用和上市公司成本的推动。公司在本季度结束时现金为120万美元，较2023年年底的210万美元减少。展望未来，Firefly计划在2025年上半年推出其获得FDA批准的脑网络分析（BNA）平台的商业运营。该公司旨在通过在美国的神经科医生采用和与药品公司的合作实现营业收入，尽管管理层指出，如果没有额外资金，公司在持续经营方面存在重大疑虑。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Jet.AI
    JTAI
    -- 6.030
    文远知行
    WRD
    -- 31.500
    Blaize Holdings
    BZAI
    -- 5.150
    金山云
    KC
    -- 20.810
    Procore Technologies
    PCOR
    -- 87.500
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    美联储暂停降息，你如何调整持仓？
    美联储宣布基准利率维持在4.25%—4.50%不变，符合市场预期。你会如何配置资产？ 展开
    联邦公开市场委员会新闻发布会，2025年1月29日